- Published at
- by manilatimes.net
positive
positive
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders
News for OSE Immunotherapeutics SA (OSE.PA)
- Published at
- by manilatimes.net
neutralneutralOSE Immunotherapeutics met à jour l’information sur les procédures en cours
OSE Immunotherapeutics provides an update on ongoing proceedings- Published at
- by manilatimes.net
neutralneutralOSE Immunotherapeutics Publishes Letter to Shareholders
OSE Immunotherapeutics Publishes Letter to Shareholders- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositiveOSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies
**media[633350,633351,633352]**- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
mixedmixedOSE Immunotherapeutics Delivers Positive Tedopi Results—Add to Your Watchlist
Stocks Analysis by Edison Group (Andrew Murphy) covering: Ose Pharma International SA. Read Edison Group (Andrew Murphy)'s latest article on Investing.com- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
neutralneutral- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
positivepositiveOSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis By Investing.com
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis- Published at
- by globenewswire.com
neutralneutralOSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
Financial highlights €18.7 million available cash as of December 31st, 2023, not including the upcoming $48 million payment as part of the recent...- Published at
- by globenewswire.com
neutralneutralOSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement
OSE Immunotherapeutics publie ses résultats financiers annuels 2023 et fait le point sur sa stratégie de développement Principaux éléments financiers ...- Published at
- by marketscreener.com
positivepositiveOSE Immunotherapeutics : Inside Information / Other news releases -March 18, 2024 at 04:21 am EDT
OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative...- Published at
- by investorideas.com
mixedmixedIncreasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Palm Beach, FL - March 5, 2024 (Investorideas.com Newswire) FN Media Group News Commentary - Pancreatic cancer is one of the leading causes of cancer death glob...